{"entity":{"type":"insider","cik":"0001469547","url":"/insider/0001469547","json_url":"/insider/0001469547.json","name":"Vivo Ventures VI, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":24,"n_filings":9,"first":"2009-08-03","last":"2016-09-01","span_basis":"filed_date"},"name_variants":[{"name":"Vivo Ventures VI, LLC","source":"filing","n_filings":9,"first_seen":"2009-08-03","last_seen":"2016-09-01"}],"transactions":[{"id":2483606,"accession":"0001225208-16-038204","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001225208-16-038204","line_url":"/filing/0001225208-16-038204","is_derivative":false,"issuer_cik":"0001305253","issuer_name":"Eiger BioPharmaceuticals, Inc.","issuer_ticker":"EIGR","issuer_name_source":null,"issuer_url":"/issuer/0001305253","owner_cik":null,"owner_name":"VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures Fund VI, L.P.; Vivo Ventures VI, LLC","owner_display_name":"VIVO VENTURES VI AFFIILATES FUND, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":187500.0,"shares_display":"187,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":1774096.0,"shares_owned_after_display":"1,774,096","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-08-18","filed_date":"2016-08-22","scope":"insider","n_lines":2},{"id":3312399,"accession":"0000904454-16-001413","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000904454-16-001413","line_url":"/filing/0000904454-16-001413","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":null,"owner_name":"Vivo Ventures Fund VI, L.P.; VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures VI, LLC","owner_display_name":"Vivo Ventures Fund VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2316.0,"shares_display":"2,316","price_per_share":13.55,"price_display":"13.55","price_state":"stated","total_value":31381.8,"total_display":"31,381.80","total_whole":"31,382","shares_owned_after":3456332.0,"shares_owned_after_display":"3,456,332","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-04-21","filed_date":"2016-09-01","scope":"insider","n_lines":2},{"id":2773155,"accession":"0000904454-16-001185","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000904454-16-001185","line_url":"/filing/0000904454-16-001185","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":null,"owner_name":"Vivo Ventures VI, LLC; VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures Fund VI, L.P.","owner_display_name":"Vivo Ventures VI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2316.0,"shares_display":"2,316","price_per_share":13.55,"price_display":"13.55","price_state":"stated","total_value":31381.8,"total_display":"31,381.80","total_whole":"31,382","shares_owned_after":3456332.0,"shares_owned_after_display":"3,456,332","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-04-21","filed_date":"2016-04-25","scope":"insider","n_lines":2},{"id":8593740,"accession":"0000904454-15-000676","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000904454-15-000676","line_url":"/filing/0000904454-15-000676","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":null,"owner_name":"Vivo Ventures Fund VI, L.P.; VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures VI, LLC","owner_display_name":"Vivo Ventures Fund VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":536017.0,"shares_display":"536,017","price_per_share":15.45,"price_display":"15.45","price_state":"stated","total_value":8281462.65,"total_display":"8,281,462.65","total_whole":"8,281,463","shares_owned_after":3458631.0,"shares_owned_after_display":"3,458,631","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-11-04","filed_date":"2015-11-04","scope":"insider","n_lines":2},{"id":8593735,"accession":"0000904454-15-000676","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000904454-15-000676","line_url":"/filing/0000904454-15-000676","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":null,"owner_name":"Vivo Ventures Fund VI, L.P.; VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures VI, LLC","owner_display_name":"Vivo Ventures Fund VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67283.0,"shares_display":"67,283","price_per_share":16.32,"price_display":"16.32","price_state":"stated","total_value":1098058.56,"total_display":"1,098,058.56","total_whole":"1,098,059","shares_owned_after":3990750.0,"shares_owned_after_display":"3,990,750","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-11-03","filed_date":"2015-11-04","scope":"insider","n_lines":2},{"id":8593729,"accession":"0000904454-15-000676","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000904454-15-000676","line_url":"/filing/0000904454-15-000676","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":null,"owner_name":"Vivo Ventures Fund VI, L.P.; VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures VI, LLC","owner_display_name":"Vivo Ventures Fund VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":93523.0,"shares_display":"93,523","price_per_share":16.8695,"price_display":"16.87","price_state":"stated","total_value":1577686.2485,"total_display":"1,577,686.25","total_whole":"1,577,686","shares_owned_after":4057543.0,"shares_owned_after_display":"4,057,543","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-11-02","filed_date":"2015-11-04","scope":"insider","n_lines":2},{"id":9269593,"accession":"0001209191-15-036216","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-036216","line_url":"/filing/0001209191-15-036216","is_derivative":false,"issuer_cik":"0001400245","issuer_name":"Carbylan Therapeutics, Inc.","issuer_ticker":"CBYL","issuer_name_source":null,"issuer_url":"/issuer/0001400245","owner_cik":null,"owner_name":"VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures Fund VI, L.P.; Vivo Ventures VI, LLC","owner_display_name":"VIVO VENTURES VI AFFIILATES FUND, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1012500.0,"shares_display":"1,012,500","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":5062500.0,"total_display":"5,062,500.00","total_whole":"5,062,500","shares_owned_after":4197198.0,"shares_owned_after_display":"4,197,198","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-04-14","filed_date":"2015-04-24","scope":"insider","n_lines":2},{"id":8459689,"accession":"0001209191-15-034049","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-15-034049","line_url":"/filing/0001209191-15-034049","is_derivative":false,"issuer_cik":"0001348911","issuer_name":"Carbylan Therapeutics, Inc.","issuer_ticker":"CBYL","issuer_name_source":null,"issuer_url":"/issuer/0001348911","owner_cik":null,"owner_name":"Vivo Ventures Fund VI, L.P.; VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures VI, LLC","owner_display_name":"Vivo Ventures Fund VI, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1012500.0,"shares_display":"1,012,500","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":5062500.0,"total_display":"5,062,500.00","total_whole":"5,062,500","shares_owned_after":4197200.0,"shares_owned_after_display":"4,197,200","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-04-14","filed_date":"2015-04-14","scope":"insider","n_lines":2},{"id":4515614,"accession":"0000904454-13-001018","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000904454-13-001018","line_url":"/filing/0000904454-13-001018","is_derivative":false,"issuer_cik":"0001369786","issuer_name":"Sagent Pharmaceuticals, Inc.","issuer_ticker":"SGNT","issuer_name_source":null,"issuer_url":"/issuer/0001369786","owner_cik":null,"owner_name":"Vivo Ventures VI, LLC; VIVO VENTURES VI AFFIILATES FUND, L.P.; Vivo Ventures Fund VI, L.P.","owner_display_name":"Vivo Ventures VI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":622700.0,"shares_display":"622,700","price_per_share":21.25,"price_display":"21.25","price_state":"stated","total_value":13232375.0,"total_display":"13,232,375.00","total_whole":"13,232,375","shares_owned_after":4150386.0,"shares_owned_after_display":"4,150,386","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-09-16","filed_date":"2013-09-17","scope":"insider","n_lines":2},{"id":5678232,"accession":"0001019687-09-002866","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001019687-09-002866","line_url":"/filing/0001019687-09-002866","is_derivative":false,"issuer_cik":"0000858803","issuer_name":"AVANIR PHARMACEUTICALS, INC.","issuer_ticker":"AVNR","issuer_name_source":null,"issuer_url":"/issuer/0000858803","owner_cik":null,"owner_name":"Vivo Ventures VI, LLC; Vivo Ventures Fund VI, L.P.","owner_display_name":"Vivo Ventures VI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":282250.0,"shares_display":"282,250","price_per_share":3.492037643932684,"price_display":"3.49","price_state":"stated","total_value":985627.625,"total_display":"985,627.62","total_whole":"985,628","shares_owned_after":8049553.0,"shares_owned_after_display":"8,049,553","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-08-11","filed_date":"2009-08-13","scope":"insider","n_lines":2},{"id":5748549,"accession":"0001019687-09-002694","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001019687-09-002694","line_url":"/filing/0001019687-09-002694#line-4","is_derivative":false,"issuer_cik":"0000858803","issuer_name":"AVANIR PHARMACEUTICALS, INC.","issuer_ticker":"AVNR","issuer_name_source":null,"issuer_url":"/issuer/0000858803","owner_cik":null,"owner_name":"Vivo Ventures VI, LLC; Vivo Ventures Fund VI, L.P.","owner_display_name":"Vivo Ventures VI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1400.0,"shares_display":"1,400","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":3080.0,"total_display":"3,080.00","total_whole":"3,080","shares_owned_after":8331803.0,"shares_owned_after_display":"8,331,803","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-07-31","filed_date":"2009-08-03","scope":"insider"},{"id":5748546,"accession":"0001019687-09-002694","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001019687-09-002694","line_url":"/filing/0001019687-09-002694#line-3","is_derivative":false,"issuer_cik":"0000858803","issuer_name":"AVANIR PHARMACEUTICALS, INC.","issuer_ticker":"AVNR","issuer_name_source":null,"issuer_url":"/issuer/0000858803","owner_cik":null,"owner_name":"Vivo Ventures VI, LLC; Vivo Ventures Fund VI, L.P.","owner_display_name":"Vivo Ventures VI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":142366.0,"shares_display":"142,366","price_per_share":2.293,"price_display":"2.29","price_state":"stated","total_value":326445.238,"total_display":"326,445.24","total_whole":"326,445","shares_owned_after":8333203.0,"shares_owned_after_display":"8,333,203","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-07-30","filed_date":"2009-08-03","scope":"insider"},{"id":5748543,"accession":"0001019687-09-002694","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001019687-09-002694","line_url":"/filing/0001019687-09-002694#line-2","is_derivative":false,"issuer_cik":"0000858803","issuer_name":"AVANIR PHARMACEUTICALS, INC.","issuer_ticker":"AVNR","issuer_name_source":null,"issuer_url":"/issuer/0000858803","owner_cik":null,"owner_name":"Vivo Ventures VI, LLC; Vivo Ventures Fund VI, L.P.","owner_display_name":"Vivo Ventures VI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":145500.0,"shares_display":"145,500","price_per_share":2.2766,"price_display":"2.28","price_state":"stated","total_value":331245.3,"total_display":"331,245.30","total_whole":"331,245","shares_owned_after":8475569.0,"shares_owned_after_display":"8,475,569","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-07-29","filed_date":"2009-08-03","scope":"insider"},{"id":5748539,"accession":"0001019687-09-002694","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001019687-09-002694","line_url":"/filing/0001019687-09-002694#line-1","is_derivative":false,"issuer_cik":"0000858803","issuer_name":"AVANIR PHARMACEUTICALS, INC.","issuer_ticker":"AVNR","issuer_name_source":null,"issuer_url":"/issuer/0000858803","owner_cik":null,"owner_name":"Vivo Ventures VI, LLC; Vivo Ventures Fund VI, L.P.","owner_display_name":"Vivo Ventures VI, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":122100.0,"shares_display":"122,100","price_per_share":2.4219,"price_display":"2.42","price_state":"stated","total_value":295713.99,"total_display":"295,713.99","total_whole":"295,714","shares_owned_after":8621069.0,"shares_owned_after_display":"8,621,069","ownership_form":"D","is_10b5_1":null,"transaction_date":"2009-07-28","filed_date":"2009-08-03","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001369786","name":"Sagent Pharmaceuticals, Inc.","url":"/issuer/0001369786","role":"Ten percent owner","n_filings":4,"first_seen":"2013-09-17","last_seen":"2016-09-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001305253","name":"Eiger BioPharmaceuticals, Inc.","url":"/issuer/0001305253","role":"Ten percent owner","n_filings":1,"first_seen":"2016-08-22","last_seen":"2016-08-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001348911","name":"Carbylan Therapeutics, Inc.","url":"/issuer/0001348911","role":"Ten percent owner","n_filings":2,"first_seen":"2015-04-14","last_seen":"2015-04-24"},{"type":"issuer","type_label":"ISSUER","cik":"0000858803","name":"AVANIR PHARMACEUTICALS, INC.","url":"/issuer/0000858803","role":"Ten percent owner","n_filings":2,"first_seen":"2009-08-03","last_seen":"2009-08-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001469547","retrieved_at":"2026-08-23T19:44:16+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}